BioArctic AB - Lecanemab winner in two categories at The Scrip ... - Marketscreener.com
| BIOA-B Stock | SEK 175.40 2.00 1.13% |
About 62% of BioArctic's investor base is looking to short. The analysis of current outlook of investing in BioArctic AB suggests that many traders are alarmed regarding BioArctic's prospects. The current market sentiment, together with BioArctic's historical and current headlines, can help investors time the market. In addition, many technical investors use BioArctic AB stock news signals to limit their universe of possible portfolio assets.
BioArctic |
BioArctic AB - Lecanemab winner in two categories at The Scrip ... Marketscreener.com
Read at news.google.com
 |
BioArctic Fundamental Analysis
We analyze BioArctic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioArctic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioArctic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
BioArctic is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
BioArctic AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioArctic stock to make a market-neutral strategy. Peer analysis of BioArctic could also be used in its relative valuation, which is a method of valuing BioArctic by comparing valuation metrics with similar companies.
Peers
BioArctic Related Equities
| ONCO | Oncopeptides | 0.57 | ||||
| CAMX | Camurus AB | 1.27 | ||||
| CANTA | Cantargia | 1.34 | ||||
| HNSA | Hansa Biopharma | 1.85 |
Complementary Tools for BioArctic Stock analysis
When running BioArctic's price analysis, check to measure BioArctic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioArctic is operating at the current time. Most of BioArctic's value examination focuses on studying past and present price action to predict the probability of BioArctic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioArctic's price. Additionally, you may evaluate how the addition of BioArctic to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |